Sabina Ciciriello1, Rachelle Buchbinder2, Richard H Osborne3, Ian P Wicks4. 1. Department of Medicine, Royal Melbourne Hospital/Western Hospital, University of Melbourne, 4th Floor Clinical Sciences Building, Royal Melbourne Hospital, Parkville, Melbourne, Victoria 3050, Australia. Electronic address: sabina.ciciriello@mh.org.au. 2. Monash Department of Clinical Epidemiology, Cabrini Hospital, Malvern, Melbourne, Victoria, Australia; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 3. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 4. Public Health Innovation, Population Health Strategic Research Centre, Faculty of Health, Deakin University, Burwood, Melbourne, Victoria, Australia.
Abstract
OBJECTIVES: To develop and test an evidence-based, multimedia patient education program (MPEP) about methotrexate (MTX) treatment for rheumatoid arthritis (RA) and a new measure of patient knowledge [Methotrexate in Rheumatoid Arthritis Knowledge test (MiRAK)]. METHODS: The content of the MPEP and MiRAK was guided by concept-mapping workshops with patients (N = 24), literature review, health professional, and expert linguistic input. The MPEP and MiRAK underwent multiple stages of testing and revision with patients and health professionals. The MiRAK was administered to RA patients (N = 169) and its properties examined using the Rasch analyses. A subset of respondents (N = 131) repeated the MiRAK to determine test-retest reliability. A before-after pilot study with patients who had recently started MTX (N = 31) tested responsiveness of the MiRAK and feasibility and acceptability of the MPEP. RESULTS: A DVD of 24-minutes duration was produced that presents detailed, evidence-based information about MTX. The Rasch analyses of the 60 MiRAK items revealed that these could be summated into a single score. The MiRAK had good model fit, supporting internal construct validity, good internal consistency (person separation index; 0.84), test-retest reliability (ICC; 0.89), and ability to detect change (ES; 2.38). The before-after study suggested that patients could self-administer the MPEP, with the majority finding it informative and easy to use. CONCLUSIONS: We developed a MPEP about MTX treatment for RA, which was found to be user-friendly and easily implementable. The MiRAK is a new scale, testing a broad spectrum of MTX knowledge. Analyses revealed strong evidence for its validity and reliability.
OBJECTIVES: To develop and test an evidence-based, multimedia patient education program (MPEP) about methotrexate (MTX) treatment for rheumatoid arthritis (RA) and a new measure of patient knowledge [Methotrexate in Rheumatoid Arthritis Knowledge test (MiRAK)]. METHODS: The content of the MPEP and MiRAK was guided by concept-mapping workshops with patients (N = 24), literature review, health professional, and expert linguistic input. The MPEP and MiRAK underwent multiple stages of testing and revision with patients and health professionals. The MiRAK was administered to RApatients (N = 169) and its properties examined using the Rasch analyses. A subset of respondents (N = 131) repeated the MiRAK to determine test-retest reliability. A before-after pilot study with patients who had recently started MTX (N = 31) tested responsiveness of the MiRAK and feasibility and acceptability of the MPEP. RESULTS: A DVD of 24-minutes duration was produced that presents detailed, evidence-based information about MTX. The Rasch analyses of the 60 MiRAK items revealed that these could be summated into a single score. The MiRAK had good model fit, supporting internal construct validity, good internal consistency (person separation index; 0.84), test-retest reliability (ICC; 0.89), and ability to detect change (ES; 2.38). The before-after study suggested that patients could self-administer the MPEP, with the majority finding it informative and easy to use. CONCLUSIONS: We developed a MPEP about MTX treatment for RA, which was found to be user-friendly and easily implementable. The MiRAK is a new scale, testing a broad spectrum of MTX knowledge. Analyses revealed strong evidence for its validity and reliability.
Authors: Francoise Fayet; Bruno Pereira; Angelique Fan; Malory Rodere; Carine Savel; Pauline Berland; Martin Soubrier; Anne Tournadre; Jean Jacques Dubost Journal: Rheumatol Int Date: 2021-05-29 Impact factor: 2.631
Authors: Anneliese J Synnot; Melanie Hawkins; Bronwen A Merner; Michael P Summers; Graziella Filippini; Richard H Osborne; Sue D P Shapland; Catherine L Cherry; Rwth Stuckey; Catherine A Milne; Paola Mosconi; Cinzia Colombo; Sophie J Hill Journal: Health Sci Rep Date: 2018-03-06
Authors: Rhiannon Phillips; Bethan Pell; Aimee Grant; Daniel Bowen; Julia Sanders; Ann Taylor; Adrian Edwards; Ernest Choy; Denitza Williams Journal: BMC Rheumatol Date: 2018-07-27